Measles Virus IgG
Enzyme ImmunoAssay (ELISA) for the semi-quantitative determination of IgG antibodies to Measles Virus in human plasma and sera. The product is intended mostly for the followup of anti Measles Virus vaccination and can also be useful for the follow up of infected individuals.
Measles, also known as rubeola, is a disease caused by a virus, specifically a paramyxovirus of the genus Morbillivirus.
Measles is spread through respiration and is highly contagious. 90% of people without immunity sharing a house with an infected person will catch it. Airborne precautions should be taken for all suspected cases of measles.
The incubation period usually lasts for 4–12 days during which there are no symptoms. Infected people remain contagious from the appearance of the first symptoms until 3–5 days after the rash appears.
In roughly the last 150 years, measles has been estimated to have killed about 200 million people worldwide.
The introduction of vaccination for Measles has radically reduced the infection among children and correlated adults.
In the last years, the introduction of ELISA kits has made possible to determine the efficacy of the vaccination and immunological response to it, providing an important tools in its follow-up.
Microplates are coated with Measles Virus native antigens derived from tissue culture of a virulent strain.
In the 1st incubation, the solid phase is treated with diluted samples and anti Measles Virus IgG are captured, if present, by the antigens.
After washing out all the other components of the sample, in the 2nd incubation bound anti Measles Virus IgG are detected by the addition of anti hIgG antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti Measles Virus IgG antibodies present in the sample.
IgG in the sample may therefore be semi quantitated in arbU/ml by means of its S/Co value and a calibration curve.
- Torrey EF and Yolken RH. 2005. Their bugs are worse than their bite. Washington Post, April 3, p. B01.
- Live attenuated measles vaccine. EPI Newsl. 1980 Feb;2(1):6.
- Rima BK, Earle JA, Yeo RP, Herlihy L, Baczko K, ter Muelen V, Carabana J, Caballero M, Celma ML, Fernandez- Munoz R 1995 Temporal and geographical distribution of measles virus genotypes. J Gen Virol 76:11731180.
- Flint SJ, Enquist LW, Racaniello VR, and AM Skalka. Principles of Virology, 2nd edition: Molecular Biology, Pathogenesis, and Control of Animal Viruses.
- “Measles kills more than 500 children so far in 2005”, IRIN, 2005-03-21. Retrieved on 2007-08-13.
- Parker A, Staggs W, Dayan G et al. (2006). “Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States”. N Engl J Med 355 (5): 447–55. PMID 16885548.
- Dillner L. “The return of the measles party”, Guardian, 2001- 07-26. Retrieved on 2007-08-13.
- Rutter M (2005). “Incidence of autism spectrum disorders: changes over time and their meaning”. Acta Paediatr 94 (1): 2–15. PMID 15858952.
- Telegraph article on increasing cases of measles 10. Measles outbreak shows a global threat – The Boston Globe. Retrieved on 2007-12-05.